EL7.AI
Strategy BuilderCOT DataAdvanced NewsResearchNewEarnings CalendarEconomic Calendar
We use cookiesPrivacy Policy
EL7.AIEL7.AI

AI Financial Intelligence
Professional analysis of central bank decisions

© 2026 EL7.AI. All rights reserved.

Markets

  • News
  • Forex
  • Stocks
  • Crypto
  • Gold
  • Commodities
  • Indices
  • ETFs

Analysis

  • Fed
  • ECB
  • BLS
  • COT
  • Economic Calendar

Learn

  • Service Guide
  • Oil

Company

  • About
  • Contact
  • Data Methodology
  • AI Disclosure
  • Pricing
  • Enterprise
  • Terms
  • Privacy
  • Security
  • WhatsApp
Status data is currently unavailable

The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Home
Stocks
Monopar Therapeutics Inc.
MNPR

MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc. · NASDAQ
Market Closed
110.26
▲ ⁦+0.27%⁩ (+0.30)
Market Cap$738.6M
Beta1.51
52w Low52w High
41.67124.82
Last Week
⁦-6.22%⁩
Last Month
⁦-5.23%⁩
Last 3 Months
⁦+81.86%⁩
Last Year
⁦+165.81%⁩
EL7 Factor Analysis
How we score this
Overall31
Weak — below market medianMomentum TrapF 3/8SafeBetter than 31% of Market stocks, per EL7's model
FactorScoreDistributionValueAvgRank
▸
Valuation
34
—17.8xBottom tier
▸
Growth
77
—7.1%Top tier
▸
Quality
14
-24.1%▼4.5%Bottom tier
▸
Safety
98
—2.6xTop tier
▸
Capital Return
53
—2.12%Around median
▸
Momentum
96
169.6%▲2.9%Top tier
▸
Sentiment
39
10▲3Bottom tier

Frequently Asked Questions

What is Monopar Therapeutics Inc. stock?▼

Monopar Therapeutics Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.

How can I invest in Monopar Therapeutics Inc.?▼

You can buy Monopar Therapeutics Inc. shares through a licensed brokerage. Research the company's financials before investing.

What are the key metrics for evaluating Monopar Therapeutics Inc.?▼

Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.

Does Monopar Therapeutics Inc. pay dividends?▼

Dividend policies vary by company. Check the dividends section on the stock page for the payout history.

What are the risks of investing in Monopar Therapeutics Inc.?▼

Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.

Fair Value
Current price$110
Analyst target · 6 analysts
$125
⁦+13%⁩
See it undervalued
Range ⁦$105–$145⁩
vs
DCF (estimate)
N/A (negative FCF)

Estimates — analyst targets and a simplified DCF, not investment advice.

Compare in the screener

AI analysis from the earnings call, financials and news

Analyst Consensus

This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.

Price Target· 6 analysts setting price target
$126.00
⁦+14.3%⁩
Current Price $110.26·Median $125.00
Low
$105.00
High
$145.00
Current price
$110.26
Average target
$126.00
Street summary

Slight Increase in Price Targets Amid Divergent Valuations

The consensus price target rose to 126 from 123.57 over one and seven days, and to 126 from 122 over 30 days, representing increases of 1.97% and 3.28%, respectively, with no change in the number of analysts, which remains at 6. The range is between 105 and 145, with a median of 125, reflecting clear divergence in estimates compared with the current price of 110.26.

As of 2026-09-11
Revisions momentum · 30d
⁦+3.3%⁩
Average rating
★ 4.23
Buy
Analyst coverage
13
Buy conviction
92%
High
Rating activity · 30d
0↑ · 0↓
Target dispersion
36%
Wide
Analyst ratings over time13 analysts rating
4
8
1
Strong BuyBuyHoldSellStrong Sell
Rating trend — last 12 months4.15 → 4.23
Recent analyst moves
  • = Reiterate2026-09-11
    Barclays
    Overweight
  • = Reiterate2026-08-17
    Morgan Stanley
    Overweight
  • = Reiterate2026-08-13
    Barclays
    Overweight
Premium content
Financial Analysis
|